Studies on the anti-angiogenic effect of *Marsdenia tenacissima* extract *in vitro* and *in vivo*

ZHENGRONG HUANG¹, HAO LIN¹, YONG WANG¹, ZHIYUN CAO², WEI LIN² and QIANG CHEN³

¹Department of Integrative Traditional Chinese and Western Medicine, Fujian Provincial Tumor Hospital, Fuzhou 350014; ²Fujian Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou 350108; ³Department of Oncology, Union Hospital of Fujian Medical University, Fuzhou 350001, P.R. China

Received September 22, 2012; Accepted December 3, 2012

DOI: 10.3892/ol.2013.1105

Abstract. *Marsdenia tenacissima*, which is widely used as an anticancer herb in traditional Chinese medicine, has been shown to possess anticancer activities. However, the underlying molecular mechanism(s) involved in the anticancer effect of this herb are poorly understood. Angiogenesis is important in the development of cancer. The main features of angiogenesis are increased vasculature and overexpression of vascular endothelial growth factor (VEGF). In the present study, the effects of *M. tenacissima* extract (MTE) on human umbilical vein endothelial cell (HUVEC) proliferation, migration and capillary-like tube formation were investigated *in vitro* and using the chick embryo chorioallantoic membrane (CAM) assay *in vivo*. It was observed that MTE inhibited the proliferation of HUVECs by blocking the cell cycle progression from G1 to S. In addition, MTE inhibited the migration and tube formation of HUVECs. MTE treatment decreased the VEGF-A expression in human hepatoma cells (HepG2), as well as the expression of VEGF-A and VEGF receptor (VEGFR)-2 in HUVECs. MTE exposure in the CAM was able to reduce the formation of blood vessels in chick embryos. Overall, the present data suggest that extracts of *M. tenacissima* may serve as potential anti-angiogenesis agents.

Introduction

Chemotherapy is one of the key tools used in the treatment of cancer, but drug resistance and severe adverse side-effects are significant obstacles (1-3). New drugs with improved features are urgently required to overcome drug resistance in various types of cancer. Natural products have been a source in the search for anticancer molecules and their further development into anticancer drugs. Traditional Chinese medicine is proving to be a promising resource for identifying drugs with anticancer activity (4,5). In recent years, interest in using natural products as therapeutic agents for cancer has increased.

*Marsdenia tenacissima*, the stem of *Marsdenia tenacissima* (Roxb.) Wight et Arn. (Family Asclepiadaceae), is grown widely in the southern provinces of China. It is used as a herbal medicine for the treatment of asthma, cancer, trachitis, tonsillitis, pharyngitis, cystitis and pneumonia (6,7). There are two major active constituents in *M. tenacissima*: phenolic acid and C21 steroidal glycosides (8). Preliminary clinical studies in China suggest that *M. tenacissima* is beneficial for treating patients with cancers such as esophageal cancer, gastric cancer and lung cancer, and has no significant side-effects (9,10). Extracts of *M. tenacissima* have been reported to have anticancer activity, inhibiting cancer growth and inducing apoptosis in several cancer cell lines *in vitro* (11-14). However, whether *M. tenacissima* inhibits tumor angiogenesis and its underlying mechanism(s) in endothelial cells remains unknown.

Angiogenesis is a crucial step for tumor growth and progression (15,16). It is a complex multistep process which includes the destabilization of established vessels, endothelial cell proliferation, migration and tubulogenesis (17). Tumor angiogenesis is a process wherein a network of blood vessels penetrates a cancerous growth to supply nutrients and oxygen and remove metabolic waste from the tumor. Tumor growth and metastasis depends heavily on angiogenesis. The induction of angiogenesis is mediated by a variety of molecules secreted from the cells within the tumors. It is well known that vascular endothelial growth factor (VEGF) is crucial in regulating angiogenesis (18) and has become a key focus of antiangiogenic therapy.

In the present study, the effect of *M. tenacissima* extract (MTE) on the antiangiogenic response was studied using *in vitro* and *in vivo* angiogenesis models. Furthermore, the possibility of MTE reacting with the vascular endothelial cells specifically through VEGF receptors was also investigated.

Materials and methods

Reagents. MTE was provided by Nanjing Sanhome pharmaceutical Co. Ltd. (Nanjing, China). RPMI-1640 medium,
Dulbecco's modified Eagle's medium (DMEM), fetal bovine serum (FBS), penicillin-streptomycin, trypsin-EDTA and TRizol reagent were purchased from Invitrogen (Carlsbad, CA, USA). The cell cycle assay kit was purchased from BD Biosciences (San Jose, CA, USA), the SuperScript II reverse transcriptase kit from Promega (Madison, WI, USA) and the in vitro angiogenesis assay kit from Millipore (Billerica, MA, USA). Human VEGF-A and VEGF receptor-2 (VEGFR-2; KDR) ELISAs were obtained from R&D Systems (Minneapolis, MN, USA). All other chemicals were purchased from Sigma Chemicals (St. Louis, MO, USA).

Cell culture. Human umbilical vein endothelial (HUVECs) and human hepatoma cells (HepG2) were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). HUVECs and HepG2 cells were grown in RPMI-1640 and DMEM, respectively, supplemented with 10% (v/v) FBS, 100 U/ml penicillin and 100 µg/ml streptomycin and incubated at 5% CO₂ in a 37°C incubator.

The study was approved by the Ethics Committee of Fujian University of Traditional Chinese Medicine, Fuzhou, China.

Cell viability assay. Cell viability was evaluated using the 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT) colorimetric assay. HUVECs were seeded into 96-well plates at 1x10⁴ cells/well. The cells were treated with 0, 2.5, 5 and 7.5 mg/ml of MTE for 24 h. At the end of the treatment, 20 µl of the MTT (5 mg/ml) was added to each well. After 4 h, MTT was removed and 100 µl of DMSO was added to each well. The absorbance was measured at 490 nm with a microplate reader (BioTek, Winooski, VT, USA). The cell viability was calculated as follows: cell viability (%) = (average absorbance of MTE-containing serum group / average absorbance of blank group) x 100.

Evaluation of cell confluency. HUVECs were seeded at a concentration of 2x10⁵ cells/well into a 6-well plate. The cells were treated with 0, 2.5, 5 and 7.5 mg/ml of MTE for 24 h. Cell confluency was evaluated using a phase-contrast microscope at a magnification of x200 (Olympus, Tokyo, Japan).

Cell cycle analysis. After incubating the HUVECs with various concentrations of MTE for 24 h, the cells were harvested and adjusted to a concentration of 1x10⁶ cells/ml. Cell cycle analysis was evaluated using flow cytometry and the percentages of G0/G1-phase, S-phase and G2/M-phase were calculated with the ModFit software (BD Biosciences).

Wound-healing assay. HUVECs were seeded at a concentration of 2x10⁵ cells/well, into a 12-well plate. Following 24 h of incubation, cells were scraped away vertically in each well using a pipette tip. Three randomly selected views along the scraped line were photographed on each well using a phase-contrast inverted microscope at x100 magnification. The cells were further treated with various concentrations of MTE (0, 2.5, 5, 7.5 mg/ml) for 24 h and another set of images was recorded. A reduction in the scraped area was considered to be the indicative of wound-healing and cell migration.

Capillary-like tube formation assay. Tube formation by HUVECs was evaluated using the in vitro angiogenesis assay kit, according to the manufacturer's instructions. After the HUVECs were treated with MTE, cells were harvested and diluted to 1x10⁵ cells in 50 µl medium. The cells were then seeded onto a solid gel of basement proteins (ECMatrix gel) in 12-well plates and incubated for 9 h at 37°C. Cellular morphology and the development of capillary tube networks were evaluated using a phase-contrast inverted microscope. Images were obtained at a magnification of x100.

VEGF-A and VEGFR-2 RT-PCR analysis. HUVECs or HepG2 cells were seeded at a concentration of 2x10⁵ cells into a 6-well plate and treated with various concentrations of MTE for 24 h. Total RNA was isolated with TRizol reagent (Invitrogen). Oligo(dT)-primed RNA (1 µg) was reverse-transcribed with SuperScript II reverse transcriptase and the cDNA was used to determine the amount of VEGF-A or VEGFR-2 mRNA by PCR with Taq DNA polymerase (Fermentas, Waltham, MA, USA) using the VEGF-A (S: GCC TTG CCT TGC TGC TCT A, AntiS: GAT GTC CAC CAG GG TCT CG), VEGFR-2 (S: ACC CCG ATT ATG TGA GA, AntiS: AGGC AGG AGT TGA GTA TGT) and GAPDH (S: GTC ATC CAT GAC AAC TTT GG, AntiS: GAG CTT GAC AAA GTG GTC GT) primers.

VEGF-A and VEGFR-2 ELISA assay. HUVECs and HepG2 cells were seeded at a concentration of 2x10⁵ cells into a 6-well plate and treated with various concentrations of MTE for 24 h. Cells were collected to measure the secretion level of VEGF-A in the two cell lines and cell lysates were used to determine the protein expression levels of VEGFR-2 in the HUVECs. The measurements were performed using the Quantikine ELISA kit, according to the manufacturer's instructions.

Chick chorioallantoic membrane (CAM) assay. A CAM assay was performed to determine the in vivo anti-angiogenic activity of MTE. MTE (1 mg) was loaded on to 0.5 cm-diameter Whatman filter paper and then applied to the CAM of a seven-day-old embryo. Following incubation for 72 h at 37°C, the angiogenesis around the filter was recorded. The number of blood vessels in a circular perimeter surrounding the implants, at a distance of 0.25 cm from the edge of the filter was counted manually.

Statistical analysis. All data are the mean of three replicates, with the exception of the CAM assays in which 10 replicates were performed for each data point. The data were analyzed using the SPSS software (Version 11.5). Statistical analysis of the data was performed using the Student's t-test and analysis of variance (ANOVA). P<0.05 was considered to indicate statistically significant differences.

Results

MTE inhibits the proliferation of HUVECs. HUVEC viability was determined following treatment with various concentrations of MTE for 24 h. Treatment with 2.5 to 7.5 mg/ml of MTE for 24 h dose dependently reduced the cell viability from 56 to 17%, when compared with the
control cells (P<0.01; Fig. 1). To further verify these results, the effect of MTE on HUVEC confluency was observed via phase-contrast microscopy. MTE treatment led to a gradual decrease in the confluency of the monolayer with the increase in drug concentration (Fig. 2).

**MTE blocks cell cycle progression in HUVECs.** To test whether the treatment of cells with MTE was able to cause cell cycle arrest, the cell cycle distribution was analyzed by flow cytometry following the treatment of the HUVECs with 0, 2.5, 5 and 7.5 mg/ml of MTE for 24 h. As shown in Fig. 3A and B, the percentage proportions of S phase cells following treatment with 0, 2.5, 5 and 7.5 mg/ml of MTE were 41.51±5.2, 37.47±4.5, 28.42±3.5 and 25.75±3.2%, respectively (P<0.01), suggesting that MTE inhibits HUVEC proliferation by blocking the cell cycle progression from G1 to S.

**MTE inhibits HUVEC migration and tubulogenesis.** To assess the antiangiogenic properties of MTE in *vitro*, its inhibitory effects on the chemotactic motility of HUVECs were investigated using the wound-healing migration assay. As shown in Fig. 4, 24 h post-wounding, untreated HUVECs migrated into the wounded (clear) area of the cell monolayer, whereas MTE treatment markedly inhibited the HUVEC migration in a dose-dependent manner. Furthermore, how MTE regulates the capillary tubule formation of HUVECs was studied. As shown in Fig. 5A and B, untreated HUVECs formed elongated tube-like structures. By contrast, MTE treatment resulted in a significant decrease in capillary tube formation in a dose-dependent manner.

**MTE suppresses the expression of VEGF-A and VEGFR-2.** To further investigate the underlying mechanism of MTE's anti-angiogenic activity, the effects of MTE on VEGF-A expression and secretion in HUVECs and HepG2 cells and...
the expression of VEGFR-2 in HUVECs were investigated. The results of the RT-PCR assay showed that MTE treatment reduced VEGF-A mRNA expression in HepG2 cells and HUVECs in a dose-dependent manner, as well as suppressing VEGFR-2 mRNA expression in HUVECs (Fig. 6A). Moreover, the protein expression patterns of VEGF-A and VEGFR-2 showed similar changes, as the mRNA levels decreased according to the MTE treatment (Fig. 6B).

MTE inhibits angiogenesis in vivo. For tumors to grow they must be able to integrate successfully with normal host tissues at the primary tumor site and metastatic sites. Tumors require a blood supply to sustain growth. Therefore, the effect of MTE on microvessel formation in vivo was studied in the CAM model. The number of vessel branch points was determined in the absence and presence of MTE. As shown in Fig. 7A and B, MTE treatment significantly reduced the total number of blood vessels in the chicken embryos when compared with the untreated control. This result provided evidence that the anti-angiogenic effects of MTE may be important in its anti-cancer activity.

Discussion

The present study demonstrates that MTE is highly effective at inhibiting cell proliferation in HUVECs by blocking the cell cycle progression from G1 to S. In addition, the present study showed that MTE inhibits endothelial cell migration and prevents vascular formation in vitro. Collectively, the present data suggest that MTE affects angiogenesis by targeting endothelial cells directly. MTE was also able to suppress the growth of blood vessels in CAM models in vivo.

Angiogenesis is important in providing nutrients and oxygen to the growing tumor (19). The process of cancer-associated angiogenesis is highly regulated, involving several growth factors and cytokines. Studies suggest that tumor growth and dissemination are dependent on the development of a neovasculature and that VEGF is a primary stimulator of angiogenesis (20). VEGF regulates vascular formation through the initiation of vessel growth, incorporation of hematopoietic and endothelial progenitor cells into the developing vasculature and inhibition of endo-
ONCOLOGY LETTERS 5: 917-922, 2013

921

thelial cell apoptosis (21). VEGF exerts its biological effects primarily through interaction with its specific receptors, VEGFRs (22,23). Although VEGF is a ligand for VEGFR-1 and VEGFR-2, VEGF signaling in angiogenesis is mainly mediated through VEGFR-2, a receptor tyrosine kinase expressed at elevated levels in endothelial and cancerous cells (24). Inhibition of VEGF/VEGFR is a key strategy in anti-angiogenic therapy for cancer. The present study showed that MTE inhibited VEGF-A and VEGFR-2 expression in HUVECs. The selective inhibition of angiogenic factors suggests that MTE has an anti-angiogenic effect, specifically through VEGF suppression. However, this requires further study, to understand whether MTE inhibits VEGF expression through other pathways.

In the present study, MTE inhibited angiogenesis in vivo and suppressed the key steps involved in angiogenesis, including proliferation, survival, migration and tubulogenesis.

Figure 6. (A) Effect of MTE on the mRNA expression levels of VEGF-A and VEGFR-2. Cells were treated with various concentrations of MTE for 24 h. The mRNA levels of VEGF-A and VEGFR-2 were determined by RT-PCR in HUVECs and HepG2s. GAPDH was used as an internal control. Data are representative of three independent experiments. (B) Effect of MTE on the protein expression levels of VEGF-A and VEGFR-2. (Bi) The protein levels of VEGF-A secreted in cell culture medium were determined by ELISA after HepG2 cells were treated with indicated concentrations of MTE for 24 h. (Bii) The protein levels of VEGF-A secreted in cell culture medium were determined by ELISA after HUVECs cells were treated with indicated concentrations of MTE for 24 h. Data are the mean ± SD (error bars) from at least three independent experiments. *P<0.01, vs. control cells. MTE, Marsdenia tenacissima extract; VEGF-A, vascular endothelial growth factor-A; VEGFR-2, vascular endothelial growth factor receptor-2; HUVEC, human umbilical vein endothelial cell; HepG2, human hepatoma cell.

Figure 7. Effect of MTE on angiogenesis in vivo. (A) A 0.5 cm-diameter filter paper loaded with 1.0 mg of MTE was applied to the chick CAM and incubated at 37°C for 72 h. The blood vessels surrounding the filter were photographed. Images are representative images of the results obtained from the two groups. Arrow: filter paper. (B) The number of blood vessels was quantified manually in a circular perimeter 0.25 cm from the edge of the filter paper inserts. Assays were performed twice with a total of 10 eggs for each tested concentration of MTE. Data are the mean ± SD (error bars). *P<0.01, vs. control. MTE, Marsdenia tenacissima extract; CAM, chorioallantoic membrane.
in endothelial cells. To the authors' knowledge, this is the first study demonstrating the expression of VEGF/VEGFR in HUVECs in response to MTE.

In conclusion, the present study demonstrated for the first time that MTE is able to inhibit tumor angiogenesis in vitro and in vivo by targeting VEGF/VEGFR in the signal pathway. The present observation of the anticancer effects of M. tenacissima not only supports its ethnopharmacological value, but also confirms its potential as a new anti-angiogenesis agent.

References
1. Boos G and Stopper H: Genotoxicity of several clinically used topoisomerase II inhibitors. Toxicol Lett 116: 7-16, 2000.
2. Longley DB, Allen WL and Johnston PG: Drug resistance, predictive markers and pharmacogenomics in colorectal cancer. Biochim Biophys Acta 1766: 184-196, 2006.
3. Nakanishi T: Drug transporters as targets for cancer chemotherapy. Cancer Genomics Proteomics 4: 241-254, 2007.
4. Ji HF, Li XJ and Zhang HY: Natural products and drug discovery. Can thousands of years of ancient medical knowledge lead us to new and powerful drug combinations in the fight against cancer and dementia? EMBO Rep 10: 194-200, 2009.
5. Zhao J, Jiang P and Zhang WD: Molecular networks for the study of TCM pharmacology. Brief Bioinform 11: 417-430, 2010.
6. Editorial Committee of the Pharmacopoeia of People’s Republic of China: The Pharmacopoeia of People’s Republic of China, Part I. Chemical Industry Press, Beijing, China, pp442-443, 2005.
7. State Administration of Traditional Chinese Medicine: Selected Works of Chinese Bencao (No. 4). Scientific and Technical Publishers, Shanghai, p7, 1999.
8. Qiu SX, Luo SQ, Lin LZ and Cordell GA: Further polyoxy-pregnanes from Marsdenia tenacissima. Phytochemistry 41: 1385-1388, 1996.
9. Wang ZL, Fan QX and Fan KS: Clinical study of Xiaoaiping in the treatment of cancer. Acta Acad Med Henan 29: 79-80, 1994.
10. Yuan XY, Fang ZG and Huang XY: Observations On the treatment of 14 cases of advanced gastric carcinoma with Inj. Xiao-Ai-Ping. J Shanghai Med Pharm 6: 12-13, 1996
11. Sun J, Shen JH, Zhang MH, Li CH and Fan ZZ: Experimental study on therapeutic function of ‘carcinoma-eliminating injection’ on cell of human gastric carcinoma. Acta Acad Shanghai Tradit Chin Med 14: 41-43, 2000.
12. Li MQ, Shen JH, Xu B and Chen J: The Mechanism of Laboratory research for Xiaoaiping treating SGC-7901 gastric carcinoma cellular strains. J Interv Radiol 10: 228-231, 2001.
13. Li D, Ouyang J, Li CP and Chen JH: Marsdenia tenacissima induces apoptosis of human U937, HL60 leukemic cells. Chin J of Biochem Pharm 29:33-37, 2008.
14. Chen B, Li CP Chen JH and Ouyang J: Effect of extract from Marsdenia tenacissima on Jurkat, Raji and RPMI8226 cells in vitro. Chin J of Biochem Pharmc 30:174-177, 2009.
15. Folkman J: Seminars in medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 333: 1757-1763, 1995.
16. Folkman J and Shing Y: Angiogenesis. J Biol Chem 267: 10931-10934, 1992.
17. Risau, W: Mechanisms of angiogenesis. Nature 386: 671-674, 1997.
18. Yi ZF, Cho SG, Zhao H, et al: A novel peptide from human apolipoprotein(a) inhibits angiogenesis and tumor growth by targeting c-Src phosphorylation in VEGF induced human umbilical endothelial cells. Int J Cancer 124: 843-852, 2009.
19. Bergers G and Benjamin LE: Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3: 401-410, 2003.
20. Hicklin DJ and Ellis LM: Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23: 1011-1027, 2005
21. Ellis LM and Hicklin DJ: VEGF-targeted therapy: mechanisms of anti-tumor activity. Nat Rev Cancer 8: 579-591, 2008
22. Ferrara N: Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol 29 (Suppl 16): 10-14, 2002.
23. Ferrara N, Gerber HP and LeCouter J: The biology of VEGF and its receptors. Nat Med 9: 669-676, 2003.
24. Shibuya M and Claesson-Welsh L: Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res 312: 549-560, 2006.